Company / Operating Cash Flow
TG Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$24.8M
FY2025
5-year range
-$295.6M / -$24.8M
FY2021-FY2025
Trend
+38.9%
vs FY2024
Sector context
#84 of 216
Health Care
What the data says
At -$25M, TG Therapeutics, Inc.'s operating cash flow ranks #84 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$296M in FY2021 to -$25M in FY2025.
Based on SEC 10-K filings.
-$25M in FY2025.
Improved from -$31M to -$25M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#84 of 216 in Health CareTop 39% of 216This company -$24.8M Sector average $658.7M
▼
-103.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 38.9% year-over-year.
- Ranks #84 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$24.8M | +38.9% |
| FY2024 | -$40.5M | -29.0% |
| FY2023 | -$31.4M | +82.2% |
| FY2022 | -$176.2M | +40.4% |
| FY2021 | -$295.6M | -37.8% |
| FY2020 | -$214.5M | -128.8% |
| FY2019 | -$93.8M | +27.3% |
| FY2018 | -$128.9M | -37.5% |
| FY2017 | -$93.8M | -52.2% |
| FY2016 | -$61.6M | -37.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026